<DOC>
	<DOCNO>NCT00506961</DOCNO>
	<brief_summary>This phase IV , randomize , open-label , parallel-arm , comparative forced- titration study compare efficacy safety rosuvastatin versus simvastatin patient type 2 DM dyslipidemia . When compare efficacy rosuvastatin 20 mg simvastatin 40 mg treatment type 2 DM dyslipidemia , rosuvastatin 20 mg superior simvastatin 40 mg achieve combined goal LDL-C ( &lt; 100 mg/dL ) non-HDL-C ( &lt; 130 mg/dL ) .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Rosuvastatin Versus Simvastatin Type 2 Diabetic Patients With Dyslipidemia</brief_title>
	<detailed_description>The duration patient participation 18 week consist 1-week screening period , 5-week lead-in period , follow 12-week treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Male female age 2075 year . 2 . Female patient post menopausal , hysterectomized childbearing potential use reliable method birth control . 3 . Diagnosed type 2 diabetes mellitus . 4 . Fasting triglyceride ≧150 mg/dL ≦500 mg/dL NonHDLC≧130 , but≦200 mg/dL 5 . Patients receive stable antidiabetic treatment 8 week randomization ( change category antidiabetic agent , dose adjustable ) . 6 . All patient give write informed consent . 1 . A history hypersensitivity statins . 2 . A history rhabdomyolysis hereditary muscle disorder . 3 . Insulintreated patient . 4 . Patient condition acute chronic pancreatitis . 5 . Creatine kinase ≧3fold upper limit normal ( ULN ) . 6 . Patients estimate creatinine clearance ( see note ) ≦30 ml/min bilirubin ≧1.5fold ULN , chronic active hepatitis liver function impairment ( AST ALT ≧3fold ULN ) . 7 . Overt proteinuria ( repeat spot urine protein &gt; 300mg/dl dipstick method ) . 8 . Patients take cyclosporine . 9 . A history homozygous familial hypercholesterolemia familial dysbetalipoproteinemia . 10 . Patients alcohol drug abuse past 3 year . 11 . Serious unstable medical psychological condition . 12 . Hypothyroidism ( TSH &gt; 5 μIU/mL ) . 13 . In investigator 's opinion , continuation study would detrimental patient 's wellbeing might confound clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>